Tag: 0001

ROCKVILLE, Md. and SUZHOU, China, July 14, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) (“Ascentage” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that Dajun Yang Dynasty Trust, an affiliate of the Company’s Chief Executive Officer, Dajun Yang, M.D., Ph.D. (the “Vendor”), proposes to offer ordinary shares, par value US$0.0001 per share, of the Company (the “Placement Shares”) in an offshore transaction outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors (the “Offshore Placement”). At the time of the closing of the Offshore Placement, the Vendor would subscribe for, and the Company would issue to the Vendor new ordinary shares of the Company (the “Replacement Shares”) at the same number as the number of the Placement Shares offered in the Offshore Placement and at the same price per share as the price per share for the Placement Shares. The closing of the transaction involving the issuance of the Replacement Shares will be subject to customary closing conditions and take place after the closing of the Offshore Placement. In connection with the Offshore Placement, the representatives in the Company’s U.S. initial public offering in January 2025 waived a lock-up restriction with respect to the Placement Shares held by the Vendor.

In week 28 of 2025, Kaldalón hf. purchased 2,544,345 of its own shares for a total consideration of ISK 61,909,963, as detailed below:

Í viku 28 árið 2025 keypti Kaldalón hf. 2.544.345 eigin hluti að kaupvirði kr. 61.909.963 skv. sundurliðun hér á eftir;

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity –

DUBLIN, July 10, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”) today announced a 1-for-35 reverse share split (the “Reverse Share Split”) of the Company’s Class A Ordinary Shares by way of a share consolidation.

MIDLAND, Texas, July 09, 2025 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) announced today that its operating company, Viper Energy Partners LLC (the “Operating Company”) has priced an offering (the “Notes Offering”) of $500,000,000 in aggregate principal amount of 4.900% senior notes that will mature on August 1, 2030 (the “2030 Notes”) and $1,100,000,000 in aggregate principal amount of 5.700% senior notes that will mature on August 1, 2035 (the “2035 Notes”, together with the 2030 Notes, the “Notes”). The price to the public was 99.902% of the principal amount for the 2030 Notes and 99.636% of the principal amount for the 2035 Notes.

On 5 February 2025, Pandora announced a new share buyback programme, cf. Company announcement no. 923. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation).
                                                                                                                                                      
The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes.

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --

Í 27. viku 2025 keypti Nova Klúbburinn hf. 2.400.000 eigin hluti að kaupverði 11.604.000 kr. í samræmi við eftirfarandi: